Comparison of antiviral assay methods using cell-free and cell-associated varicella-zoster virus.
Assay methods for varicella-zoster virus (VZV) susceptibility to acyclovir (ACV) of VZV were compared by using cell-free (CF) and cell-associated (CA) virus of 6 x plaque-purified VZV. The 50% effective doses (ED50) of ACV, as required to reduce virus plaque formation by 50%, were about 8 times higher for CA virus than for CF virus. Also, the ED50 of 1-beta-D-arabinofuranosyl-(E)-5-(2-bromovinyl)uracil (BVaraU) for CA-VZV was higher than for CF-VZV, and fresh clinical isolates of VZV gave higher ACV ED50 values than CF virus. CA virus prepared at various times after CF virus infection showed a gradual increase of the ACV ED50 with time, ranging from the ED50 for CF virus to that for CA virus.
Shiraki
K
K
Department of Virology, Toyama Medical and Pharmaceutical University, Japan.
Ochiai
H
H
Namazue
J
J
Okuno
T
T
Ogino
S
S
Hayashi
K
K
Yamanishi
K
K
Takahashi
M
M
D000212:Acyclovir / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives / Q000494:pharmacology; D002474:Cell-Free System; D004261:DNA Replication / Q000187:drug effects; D004279:DNA, Viral / Q000096:biosynthesis; D014645:Herpesvirus 3, Human / Q000187:drug effects*; D006801:Humans; D009693:Nucleic Acid Hybridization; D010948:Viral Plaque Assay; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D004279:DNA, Viral; D001086:Arabinofuranosyluracil; C031368:sorivudine; D000212:Acyclovir